174 related articles for article (PubMed ID: 36371988)
21. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway.
Nan L; Qin T; Xiao Y; Qian W; Li J; Wang Z; Ma J; Ma Q; Wu Z
Cell Transplant; 2019; 28(9-10):1289-1298. PubMed ID: 31161784
[TBL] [Abstract][Full Text] [Related]
22. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling.
Ide T; Kitajima Y; Miyoshi A; Ohtsuka T; Mitsuno M; Ohtaka K; Miyazaki K
Ann Surg Oncol; 2007 Sep; 14(9):2600-7. PubMed ID: 17534684
[TBL] [Abstract][Full Text] [Related]
23. HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes.
Cui J; Xia T; Xie D; Gao Y; Jia Z; Wei D; Wang L; Huang S; Quan M; Xie K
Oncogene; 2016 Sep; 35(36):4708-18. PubMed ID: 26876216
[TBL] [Abstract][Full Text] [Related]
24. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
25. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
[TBL] [Abstract][Full Text] [Related]
26. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic stellate cells increase pancreatic cancer cells invasion through the hepatocyte growth factor /c-Met/survivin regulated by P53/P21.
Yang XP; Liu SL; Xu JF; Cao SG; Li Y; Zhou YB
Exp Cell Res; 2017 Aug; 357(1):79-87. PubMed ID: 28461158
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer.
Lara MS; Holland WS; Chinn D; Burich RA; Lara PN; Gandara DR; Kelly K; Mack PC
Clin Lung Cancer; 2017 May; 18(3):281-285. PubMed ID: 28038979
[TBL] [Abstract][Full Text] [Related]
29. Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells.
Usatyuk PV; Fu P; Mohan V; Epshtein Y; Jacobson JR; Gomez-Cambronero J; Wary KK; Bindokas V; Dudek SM; Salgia R; Garcia JG; Natarajan V
J Biol Chem; 2014 May; 289(19):13476-91. PubMed ID: 24634221
[TBL] [Abstract][Full Text] [Related]
30. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
[TBL] [Abstract][Full Text] [Related]
31. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
Castoldi R; Ecker V; Wiehle L; Majety M; Busl-Schuller R; Asmussen M; Nopora A; Jucknischke U; Osl F; Kobold S; Scheuer W; Venturi M; Klein C; Niederfellner G; Sustmann C
Oncogene; 2013 Dec; 32(50):5593-601. PubMed ID: 23812422
[TBL] [Abstract][Full Text] [Related]
32. HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells.
Matsumura A; Kubota T; Taiyoh H; Fujiwara H; Okamoto K; Ichikawa D; Shiozaki A; Komatsu S; Nakanishi M; Kuriu Y; Murayama Y; Ikoma H; Ochiai T; Kokuba Y; Nakamura T; Matsumoto K; Otsuji E
Int J Oncol; 2013 Feb; 42(2):535-42. PubMed ID: 23233163
[TBL] [Abstract][Full Text] [Related]
33. Hypoxic pancreatic stellate cell-derived exosomal mirnas promote proliferation and invasion of pancreatic cancer through the PTEN/AKT pathway.
Cao W; Zeng Z; He Z; Lei S
Aging (Albany NY); 2021 Feb; 13(5):7120-7132. PubMed ID: 33653966
[TBL] [Abstract][Full Text] [Related]
34. Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer.
Sharma R; Malviya R
Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188869. PubMed ID: 36842767
[TBL] [Abstract][Full Text] [Related]
35. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
Holland WS; Chinn DC; Lara PN; Gandara DR; Mack PC
J Cancer Res Clin Oncol; 2015 Apr; 141(4):615-26. PubMed ID: 25323938
[TBL] [Abstract][Full Text] [Related]
36. Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer.
Kitajima Y; Ide T; Ohtsuka T; Miyazaki K
Cancer Sci; 2008 Jul; 99(7):1341-7. PubMed ID: 18422749
[TBL] [Abstract][Full Text] [Related]
37. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
38. EGFR is dispensable for c-Met-mediated proliferation and survival activities in mouse adult liver oval cells.
Martínez-Palacián A; Del Castillo G; Herrera B; Fernández M; Roncero C; Fabregat I; Sánchez A
Cell Signal; 2012 Feb; 24(2):505-513. PubMed ID: 22001397
[TBL] [Abstract][Full Text] [Related]
39. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.
Gusenbauer S; Vlaicu P; Ullrich A
Oncogene; 2013 Aug; 32(33):3846-56. PubMed ID: 23045285
[TBL] [Abstract][Full Text] [Related]
40. Ascitic fluid shear stress in concert with hepatocyte growth factor drive stemness and chemoresistance of ovarian cancer cells via the c-Met-PI3K/Akt-miR-199a-3p signaling pathway.
Hassan AA; Artemenko M; Tang MKS; Shi Z; Chen LY; Lai HC; Yang Z; Shum HC; Wong AST
Cell Death Dis; 2022 Jun; 13(6):537. PubMed ID: 35676254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
